SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense volatility and trading volume as community members debate whether the rally is a legitimate breakout driven by upcoming music festival partnerships or a manipulated pump-and-dump scheme. Investors remain sharply divided, with some highlighting the project's real-world event utility and future roadmap as catalysts for growth, while others express concerns over high wallet concentration and potential regulatory investigation.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is generating significant community buzz as traders weigh its potential as an undervalued DeFi leader against broader market volatility and governance-related news. While some participants are actively accumulating on dips in anticipation of a parabolic breakout, others remain focused on technical support levels and ongoing debates regarding its long-term stability compared to other lending protocols.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining significant traction as investors reconnect with its 2011 origin as the original parody token, with community members highlighting its deep historical roots, locked supply, and organic narrative as drivers for potential long-term growth. While some skeptics dismiss it as a joke, proponents are actively comparing it to early memecoin successes and emphasizing its status as a foundational piece of crypto culture that is currently undergoing a massive resurgence.

Procure ETF Trust II - Procure Space ETF

The Procure Space ETF ($UFO) is attracting significant community attention as investors position themselves for the potential IPO of SpaceX and the broader expansion of the commercial space economy. While some community members appreciate the ETF for its broad exposure to industry leaders, others are debating whether its diverse holdings truly constitute a 'pure play' on space, leading to discussions about alternative investment strategies.

Daddy Darth Vader

The community is engaged in a speculative "Daddy Wars" narrative involving DARTH, SIDIOUS, and MAULCOIN, with participants actively debating the leadership and future trajectory of these low market cap tokens. Supporters are highlighting aggressive community-driven marketing and token giveaways, while skeptics warn of volatility and the risks inherent in such nano-cap assets.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining community traction as investors highlight its position in pre-IPO exposure and long-term potential within the AI crypto sector. Discussions emphasize its micro-cap status and emerging utility as a speculative alternative to established AI-focused projects.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a significant policy shift following a new executive order that accelerates FDA review pathways for psychedelic-based therapies, including LSD. Investors are actively debating the potential for a sector-wide re-rating and identifying candidates for future M&A, as Definium remains in focus with multiple Phase 3 trial readouts scheduled throughout the year.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a major breakout, driven by the token's cybersecurity utility and its low-float, supply-constrained profile. Traders are actively debating accumulation strategies and sharing bullish sentiment regarding potential partnerships and the broader altcoin market cycle.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum is capturing market attention as a low-float, software-focused quantum computing play that investors are comparing to early-stage operating system developers. Community discussion is centered on its strategic partnerships with major industry players and its potential to benefit from a rotation of liquidity into the quantum sector.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Twist Bioscience is generating strong buzz as investors weigh its robust revenue growth and expanding market reach against skepticism regarding the firm's path to consistent profitability. The community is actively debating the company's long-term potential as a foundational "picks and shovels" provider for the biotechnology sector while closely monitoring insider trading activity and recent revenue guidance upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

Equity

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.


Compass Pathways (NASDAQ:CMPS) Sees Large Volume Increase - What's Next?

Compass Pathways (NASDAQ:CMPS) Sees Unusually-High Trading Volume - Still a Buy...

Short Interest in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Rises By 39.5%

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest...

Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness

Compass Pathways (NASDAQ:CMPS) executives outlined the company's latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami Fadia.

Phase 3 results highlighted rapid and durable antidepressant effects
CEO Kabir Nath said the...

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based...

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are currently covering the company, Marketbeat Ratings...

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees...

Compass Pathways PLC Sponsored ADR $CMPS Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 169.0% during the fourth quarter, according to the company in...

Compass Pathways (NASDAQ:CMPS) Given New $18.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group cut their price target on shares of Compass Pathways from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Current Price	$6.66
Prev Close	$6.66
Open	$6.80
Dividend Yield	0.00%
50-Day Moving Average	$6.38
Beta	1.39
Avg. Volume	2.45M
PE Ratio	-2.18

52-Week High	$8.90
52-Week Low	$2.25
Market Capitalization	$639.93M
EPS (Annual)	-$3.09
Price to Book	-12.11
Revenue Per Employee	$0.00

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMPS News

CMPSCOMPASS Pathways